Luca Dozza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Luca Dozza has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Elisa Mikus
Cardiovascular Department, Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola, RA, Italy
3 shared publications Simone Calvi
Department of Cardiothoracic and Vascular Surgery Anesthesia, Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA)
3 shared publications- Aneta Aleksova
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Azienda Sanitaria Universitaria Giuliano Isontina, Cardiothoracovascular Department, Trieste, Italy
2 shared publications Caterina Simon
USC Cardiochirurgia ASST Papa Giovanni XXIII, Bergamo, Italy (C.S.).
2 shared publications- Dariush Mozaffarian
Tufts University
2 shared publications Mauro Del Giglio
Department of Cardiothoracic and Vascular Surgery Anesthesia, Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA)
2 shared publications
Latest Publications
- 12 July 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (8) , e008382
Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation
Background: Postoperative atrial fibrillation (POAF) occurs in 30% to 50% of patients undergoing cardiac surgery and is associated with increased morbidity and mortality. Prospective identification of structural/molecular changes in atrial myocardium that correlate with myocardial injury and precede and predict risk of POAF may identify new molecular pathways and targets for prevention of this common morbid complication. Methods: Right atrial appendage samples were prospectively collected during cardiac surgery from 239 patients enrolled in the OPERA trial (Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation), fixed in 10% buffered formalin, and embedded in paraffin for histology. We assessed general tissue morphology, cardiomyocyte diameters, myocytolysis (perinuclear myofibril loss), accumulation of perinuclear glycogen, interstitial fibrosis, and myocardial gap junction distribution. We also assayed NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-cTnT, CRP (C-reactive protein), and circulating oxidative stress biomarkers (F2-isoprostanes, F3-isoprostanes, isofurans) in plasma collected before, during, and 48 hours after surgery. POAF was defined as occurrence of postcardiac surgery atrial fibrillation or flutter of at least 30 seconds duration confirmed by rhythm strip or 12-lead ECG. The follow-up period for all arrhythmias was from surgery until hospital discharge or postoperative day 10. Results: Thirty-five percent of patients experienced POAF. Compared with the non-POAF group, they were slightly older and more likely to have chronic obstructive pulmonary disease or heart failure. They also had a higher European System for Cardiac Operative Risk Evaluation and more often underwent valve surgery. No differences in left atrial size were observed between patients with POAF and patients without POAF. The extent of atrial interstitial fibrosis, cardiomyocyte myocytolysis, cardiomyocyte diameter, glycogen score or Cx43 distribution at the time of surgery was not significantly associated with incidence of POAF. None of these histopathologic abnormalities were correlated with levels of NT-proBNP, hs-cTnT, CRP, or oxidative stress biomarkers. Conclusions: In sinus rhythm patients undergoing cardiac surgery, histopathologic changes in the right atrial appendage do not predict POAF. They also do not correlate with biomarkers of cardiac function, inflammation, and oxidative stress. Graphic A graphic abstract is available for this article.
- 12 July 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (8) , e008382
Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation
Background: Postoperative atrial fibrillation (POAF) occurs in 30% to 50% of patients undergoing cardiac surgery and is associated with increased morbidity and mortality. Prospective identification of structural/molecular changes in atrial myocardium that correlate with myocardial injury and precede and predict risk of POAF may identify new molecular pathways and targets for prevention of this common morbid complication. Methods: Right atrial appendage samples were prospectively collected during cardiac surgery from 239 patients enrolled in the OPERA trial (Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation), fixed in 10% buffered formalin, and embedded in paraffin for histology. We assessed general tissue morphology, cardiomyocyte diameters, myocytolysis (perinuclear myofibril loss), accumulation of perinuclear glycogen, interstitial fibrosis, and myocardial gap junction distribution. We also assayed NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-cTnT, CRP (C-reactive protein), and circulating oxidative stress biomarkers (F2-isoprostanes, F3-isoprostanes, isofurans) in plasma collected before, during, and 48 hours after surgery. POAF was defined as occurrence of postcardiac surgery atrial fibrillation or flutter of at least 30 seconds duration confirmed by rhythm strip or 12-lead ECG. The follow-up period for all arrhythmias was from surgery until hospital discharge or postoperative day 10. Results: Thirty-five percent of patients experienced POAF. Compared with the non-POAF group, they were slightly older and more likely to have chronic obstructive pulmonary disease or heart failure. They also had a higher European System for Cardiac Operative Risk Evaluation and more often underwent valve surgery. No differences in left atrial size were observed between patients with POAF and patients without POAF. The extent of atrial interstitial fibrosis, cardiomyocyte myocytolysis, cardiomyocyte diameter, glycogen score or Cx43 distribution at the time of surgery was not significantly associated with incidence of POAF. None of these histopathologic abnormalities were correlated with levels of NT-proBNP, hs-cTnT, CRP, or oxidative stress biomarkers. Conclusions: In sinus rhythm patients undergoing cardiac surgery, histopathologic changes in the right atrial appendage do not predict POAF. They also do not correlate with biomarkers of cardiac function, inflammation, and oxidative stress. Graphic A graphic abstract is available for this article.
- 24 October 2017
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (12) , 2071-2078
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.
- 24 October 2017
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (12) , 2071-2078
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.
- 1 November 2015
- Vol. 24 (6) , 693-698
Right Anterior Mini-Thoracotomy: A 'New Gold Standard' for Aortic Valve Replacement?
Details are provided of the authors' four-year experience with minimally invasive aortic valve replacement (AVR) through a right mini-thoracotomy, using totally central cannulation. Between November 2011 and October 2014, a total of 248 patients (143 males, 105 females; mean age 72.6 ± 11.5 years; range: 29-93 years) underwent isolated AVR through a right anterior mini-thoracotomy with total arterial and venous central cannulation. AVR was performed through a 4- to 6-cm skin incision at the third intercostal space. The overall cardiopulmonary bypass time was 60.4 ± 16.7 min, and the aortic cross-clamp time 47.5 ± 14.1 min. A biological prosthesis was implanted in 242 patients (97.6%), using running sutures. The median intensive care unit and hospital stays were 40.5 h (IQR 24.6) and six days (IQR 6.0), respectively. In-hospital mortality was 1.2% (3/248); among 86 patients operated on during 2014 the hospital mortality was zero. AVR performed via a right mini-thoracotomy with total central cannulation provided encouraging results. Adequate surgeon experience, in addition to technical expedience, are of utmost importance as demonstrated by the progressive and steady reduction in operating times. This approach may become highly competitive to a standard full sternotomy, and could become the 'new gold standard' for aortic valve surgery in the near future.
- 1 November 2015
- Vol. 24 (6) , 693-698
Right Anterior Mini-Thoracotomy: A 'New Gold Standard' for Aortic Valve Replacement?
Details are provided of the authors' four-year experience with minimally invasive aortic valve replacement (AVR) through a right mini-thoracotomy, using totally central cannulation. Between November 2011 and October 2014, a total of 248 patients (143 males, 105 females; mean age 72.6 ± 11.5 years; range: 29-93 years) underwent isolated AVR through a right anterior mini-thoracotomy with total arterial and venous central cannulation. AVR was performed through a 4- to 6-cm skin incision at the third intercostal space. The overall cardiopulmonary bypass time was 60.4 ± 16.7 min, and the aortic cross-clamp time 47.5 ± 14.1 min. A biological prosthesis was implanted in 242 patients (97.6%), using running sutures. The median intensive care unit and hospital stays were 40.5 h (IQR 24.6) and six days (IQR 6.0), respectively. In-hospital mortality was 1.2% (3/248); among 86 patients operated on during 2014 the hospital mortality was zero. AVR performed via a right mini-thoracotomy with total central cannulation provided encouraging results. Adequate surgeon experience, in addition to technical expedience, are of utmost importance as demonstrated by the progressive and steady reduction in operating times. This approach may become highly competitive to a standard full sternotomy, and could become the 'new gold standard' for aortic valve surgery in the near future.
- 1 March 2015
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 99 (3) , 826-830
Aortic Valve Replacement Through Right Minithoracotomy: Is it Really Biologically Minimally Invasive?
- 1 March 2015
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 99 (3) , 826-830
Aortic Valve Replacement Through Right Minithoracotomy: Is it Really Biologically Minimally Invasive?
- Open Access
- 1 January 2015
- Vol. 4 (1) , 67-70-70
Minimally invasive reoperative aortic valve replacement
Minimally invasive reoperative aortic valve replacement
- 1 January 2015
- Vol. 4 (1) , 67-70-70
Open AccessMinimally invasive reoperative aortic valve replacement
Minimally invasive reoperative aortic valve replacement
- 15 December 2014
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 45 (2) , 170-178
Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial
Background: Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery and predicts increased morbidity and mortality. Identification of patients at high risk of POAF with the help of circulating biomarkers may enable early preventive treatment but data are limited, especially in contemporary surgical patients.Methods: Plasma concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity cardiac troponin T (hs‐cTnT) were measured at enrolment, on the morning of cardiac surgery, at end surgery, and 2 days postsurgery in 562 patients undergoing cardiac surgery, randomized to perioperative supplementation with oral fish oil or placebo in the Omega‐3 Fatty Acids for Prevention of Post‐Operative Atrial Fibrillation trial (OPERA). The primary endpoint was incident POAF lasting ≥ 30 s, centrally adjudicated and confirmed electrocardiographically.Results: Higher levels of NT‐proBNP and hs‐cTnT before surgery were associated with older age, renal or cardiac dysfunction and EuroSCORE. NT‐proBNP peaked on postoperative day 2 (2172 [1238–3758] ng/L, median [Q1–Q3]), while hs‐cTnT peaked at the end of surgery (373 [188–660] ng/L). Fish oil supplementation did not alter the time course of the cardiac biomarkers (P > 0·05). Concentrations of NT‐proBNP or hs‐cTnT, on the morning of surgery, or changes in their level between morning of surgery and postsurgery, were not significantly associated with POAF after adjustment for clinical and surgical characteristics.Conclusion: Among patients undergoing cardiac surgery, NT‐proBNP and hs‐cTnT are related to clinical and surgical characteristics, have different perioperative time courses but are not independently associated with risk of POAF.
- 15 December 2014
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 45 (2) , 170-178
Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial
Background: Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery and predicts increased morbidity and mortality. Identification of patients at high risk of POAF with the help of circulating biomarkers may enable early preventive treatment but data are limited, especially in contemporary surgical patients.Methods: Plasma concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity cardiac troponin T (hs‐cTnT) were measured at enrolment, on the morning of cardiac surgery, at end surgery, and 2 days postsurgery in 562 patients undergoing cardiac surgery, randomized to perioperative supplementation with oral fish oil or placebo in the Omega‐3 Fatty Acids for Prevention of Post‐Operative Atrial Fibrillation trial (OPERA). The primary endpoint was incident POAF lasting ≥ 30 s, centrally adjudicated and confirmed electrocardiographically.Results: Higher levels of NT‐proBNP and hs‐cTnT before surgery were associated with older age, renal or cardiac dysfunction and EuroSCORE. NT‐proBNP peaked on postoperative day 2 (2172 [1238–3758] ng/L, median [Q1–Q3]), while hs‐cTnT peaked at the end of surgery (373 [188–660] ng/L). Fish oil supplementation did not alter the time course of the cardiac biomarkers (P > 0·05). Concentrations of NT‐proBNP or hs‐cTnT, on the morning of surgery, or changes in their level between morning of surgery and postsurgery, were not significantly associated with POAF after adjustment for clinical and surgical characteristics.Conclusion: Among patients undergoing cardiac surgery, NT‐proBNP and hs‐cTnT are related to clinical and surgical characteristics, have different perioperative time courses but are not independently associated with risk of POAF.
- 1 April 2013
- Vol. 54 (2) , 235-53
BRAVISSIMO: 12-month results from a large scale prospective trial.
The BRAVISSIMO study is a prospective, non-randomized, multi-center, multi-national, monitored trial, conducted at 12 hospitals in Belgium and 11 hospitals in Italy. This manuscript reports the findings up to the 12-month follow-up time point for both the TASC A&B cohort and the TASC C&D cohort. The primary endpoint of the study is primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR) within 12 months. Between July 2009 and September 2010, 190 patients with TASC A or TASC B aortoiliac lesions and 135 patients with TASC C or TASC D aortoiliac lesions were included. The demographic data were comparable for the TASC A/B cohort and the TASC C/D cohort. The number of claudicants was significantly higher in the TASC A/B cohort, The TASC C/D cohort contains more CLI patients. The primary patency rate for the total patient population was 93.1%. The primary patency rates at 12 months for the TASC A, B, C and D lesions were 94.0%, 96.5%, 91.3% and 90.2% respectively. No statistical significant difference was shown when comparing these groups. Our findings confirm that endovascular therapy, and more specifically primary stenting, is the preferred treatment for patients with TASC A, B, C and D aortoiliac lesions. We notice similar endovascular results compared to surgery, however without the invasive character of surgery.
- 1 April 2013
- Vol. 54 (2) , 235-53
BRAVISSIMO: 12-month results from a large scale prospective trial.
The BRAVISSIMO study is a prospective, non-randomized, multi-center, multi-national, monitored trial, conducted at 12 hospitals in Belgium and 11 hospitals in Italy. This manuscript reports the findings up to the 12-month follow-up time point for both the TASC A&B cohort and the TASC C&D cohort. The primary endpoint of the study is primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR) within 12 months. Between July 2009 and September 2010, 190 patients with TASC A or TASC B aortoiliac lesions and 135 patients with TASC C or TASC D aortoiliac lesions were included. The demographic data were comparable for the TASC A/B cohort and the TASC C/D cohort. The number of claudicants was significantly higher in the TASC A/B cohort, The TASC C/D cohort contains more CLI patients. The primary patency rate for the total patient population was 93.1%. The primary patency rates at 12 months for the TASC A, B, C and D lesions were 94.0%, 96.5%, 91.3% and 90.2% respectively. No statistical significant difference was shown when comparing these groups. Our findings confirm that endovascular therapy, and more specifically primary stenting, is the preferred treatment for patients with TASC A, B, C and D aortoiliac lesions. We notice similar endovascular results compared to surgery, however without the invasive character of surgery.